Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Takeda Pharmaceutical said on October 23 that its CLDN18.2-targeting antibody drug conjugate (ADC) licensed from Chinese biotech Innovent Biologics met both primary endpoints in a PIII trial in advanced gastric cancer. The G-HOPE-001 study examined arcotatug tavatecan, also known as…
To read the full story
Related Article
- Takeda Closes Innovent Oncology Deal, Bags Rights to 2 Late-Stage Assets
December 8, 2025
- Takeda, Innovent Ink Oncology Deal for Bispecific, ADC Therapies
October 23, 2025
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





